

Special Issue

Review Special Issue Series: Recent Advances in Live Vaccines against Protozoan Parasites

Message from the Guest Editor

In this Special Issue we would like to focus on **the development, characterization, field trials and efficacy tests of live vaccines developed for protozoan parasites affecting animals and humans, with a special interest in, but not limited to, those related to apicomplexan parasites and/or with zoonotic potential.** To this end, we invite you to submit an **original research** or **review article** to this Special Issue. The following topics are intended to serve as guidance, and other related subjects are welcome: Vaccines against intracellular parasites (e.g., apicomplexan parasites); Vaccines against extracellular parasites (e.g., flagellates, ciliates); Vaccines using low-virulence strains of protozoan parasites isolated from field samples; Vaccines using genetically modified organisms of protozoan parasites (knockout, exogenous expression of heterologous proteins/antigens, etc.), with a special interest in CRISPR/Cas9 techniques; Vaccines against diseases caused by protozoan parasites that are transmitted to humans through animal products (meat, milk, eggs, etc.)—One health approach.

Guest Editor

Dr. David Arranz-Solís

Animal Health Department, Faculty of Veterinary Sciences,
Complutense University of Madrid, Madrid, Spain

Deadline for manuscript submissions

closed (1 November 2023)



Vaccines

an Open Access Journal
by MDPI

Impact Factor 3.4
CiteScore 9.9
Indexed in PubMed



mdpi.com/si/148487

Vaccines
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
vaccines@mdpi.com

[mdpi.com/journal/
vaccines](https://mdpi.com/journal/vaccines)





Vaccines

an Open Access Journal
by MDPI

Impact Factor 3.4
CiteScore 9.9
Indexed in PubMed



[mdpi.com/journal/
vaccines](https://mdpi.com/journal/vaccines)



About the Journal

Message from the Editor-in-Chief

Vaccines (ISSN 2076-393X) has had a 6-year history of publishing peer-reviewed state of the art research that advances the knowledge of immunology in human disease protection. Immunotherapeutics, prophylactic vaccines, immunomodulators, adjuvants and the global differences in regulatory affairs are some of the highlights of the research published that have shaped global health. Our open access policy allows all researchers and interested parties to immediately scrutinize the rigorous evidence our publications have to offer. We are proud to present the work and perspectives of many to contribute to future decisions concerning human health.

Editor-in-Chief

Prof. Dr. Ralph A. Tripp

Department of Infectious Diseases, College of Veterinary Medicine,
University of Georgia, Athens, GA 30602-7387, USA

Author Benefits

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPIus / SciFinder, and other databases.

Journal Rank:

JCR - Q2 (Medicine, Research and Experimental) /
CiteScore - Q1 (Pharmacology (medical))

Rapid Publication:

manuscripts are peer-reviewed and a first decision is provided to authors approximately 19.6 days after submission; acceptance to publication is undertaken in 2.8 days (median values for papers published in this journal in the first half of 2025).